Injection training for the 2026 at-home Leqembi regimen teaches patients and caregivers to give the weekly starter shots safely under clinician oversight. Reading the headline carefully means seeing home injections as a new delivery option for eligible early disease, not a treatment without tests and monitoring. Leqembi Iqlik is a once-weekly shot containing lecanemab-irmb for early Alzheimer's disease. Early Alzheimer's disease here means mild cognitive impairment or mild dementia caused by Alzheimer's.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from NIH — Use this primary source to verify the official guidance.
- Apply through Multivu’s official page — Use this page to review requirements and apply directly.
Table of Contents
- Who Qualifies for the Starter Shots?
- Why Do Tests Still Come First?
- What Does Injection Training Cover?
- What Monitoring Continues at Home?
Who Qualifies for the Starter Shots?
The starter shots are only for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. The DailyMed FDA label uses early Alzheimer's disease as the umbrella term for those two stages in the current prescribing information.
That limit matters for families reading headlines. Moderate or severe dementia falls outside the approval, as does memory loss without Alzheimer's as the cause. Ask the diagnosing clinic which stage and cause appear in your record.
Why Do Tests Still Come First?
Treatment also requires proof of amyloid-beta buildup before the first dose. The FDA labeling summary points to PET scans or spinal-fluid testing as the usual confirmation in the labeling summary.
Home injections do not replace that workup. Plan for referrals, scan scheduling, and records transfer before you practice injections. Families who start with testing avoid delays once training begins.
What Does Injection Training Cover?
Eisai and Biogen state in the approval announcement that initiation is 500 mg once weekly as two back-to-back 250-mg autoinjector shots, each taking about 15 seconds. Training turns those seconds into a repeatable routine.
Medscape's clinical summary and the Alzheimer's Association stress that caregiver and patient training plus clinician oversight stay central. Prior maintenance approval already allowed home use after IV start, so many clinics have a coaching model to build on.
- Confirm who will give each shot and who serves as backup
- Practice device setup, skin site selection, timing, and disposal with the nurse
- Review storage, handling, missed-dose rules, and when to call the clinic
- Log dates, sites, and questions for the prescribing team
What Monitoring Continues at Home?
Medscape's clinical summary in an August clinical review notes lecanemab carries a boxed warning for brain swelling or bleeding linked to amyloid imaging abnormalities, with baseline and follow-up brain MRIs required. Home dosing changes the setting, not the scan plan. Eisai and Biogen report that initiation approval rested on similar drug levels and amyloid clearance versus IV in Clarity AD extension substudies, not a separate large starter-shot outcome trial.
After 18 months of initiation treatment, patients may stay on that regimen or move to 360 mg weekly maintenance, with switches between IV and under-skin dosing allowed. Keep a folder with amyloid results, MRI dates, dose logs, and clinic contacts. Bring it, plus caregiver questions about technique, to each visit.
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: How People With Mild Cognitive Impairment Can Read the FDA Headline Carefully
- MRI and ARIA Monitoring With At-Home Leqembi in 2026: How People With Mild Cognitive Impairment Can Read the FDA Headline Carefully
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: How People With Mild Cognitive Impairment Can Compare Testing Options
